Biopharmaceutical Manufacturing Market

The global biopharmaceutical manufacturing market reached a volume of US$ 5.4 Million Liters in 2018, growing at a CAGR of 11.6% during 2011-2018. The manufacturing of biopharmaceuticals (biopharma) is characterized by a highly complex research and development (R&D) setting, which includes the use of technologies that are harnessed by new scientific advances. The production process of biopharmaceuticals supports a wide range of production-related, highly specialized jobs. Some of these employments include packaging and filling machine operators and tenders, blending and mixing machine setters, and testers, inspectors, samplers, sorters, and chemical equipment operators. Different methods can be deployed for the production of biopharmaceuticals, which include continuous and follow-on manufacturing systems. In the continuous system, raw materials are fed continuously from one end into the process and the finished product is extracted from the other end. On the other hand, the follow-on product development mostly includes the adoption of both current and legacy bioprocessing technologies to obtain a cost-effective procedure to make drugs.

With the emergence of the industrial revolution 4.0, biopharma manufacturers have been increasingly using a digitized paradigm that involves machines to collect, process and produce data, then communicate it with other machines through the Industrial Internet of Things (IIoT). These next-generation technologies have helped industry players to increase process understanding with the provision of more data with advanced modeling techniques and analytics. Besides this, expansion in the biopharma industry has led to the emerging trend of outsourcing due to high costs, and lack of expertise in in-house manufacturing. As a result, contract manufacturing organizations (CMOs) are investing heavily to expand their existing capabilities and capacities. Most of these firms are based across developed regions. However, the advent of advanced manufacturing methods and technologies in emerging economies, like India and China, has led to a significant shift in the market. Also, the industry currently accounts for a sophisticated, specialized and highly regulated field with outsized economic contributions across the globe. Looking forward, IMARC Group expects the market to grow at a CAGR of 10.4% during 2019-2024, reaching a volume of 9.9 Million Liters by 2024.

Breakup by Cell Culture:

• Mammalian
• Microbial

At present, mammalian cell culture is the largest segment in the market.

Breakup by Class:

• Monoclonal Antibodies
• Recombinant Proteins
• Interferon
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Erythropoietin
• Recombinant Human Insulin
• Vaccines
• Human Growth Hormones (HGH)

Amongst the above-mentioned categories, recombinant proteins dominate the market.

Regional Insights:

• North America
• Europe
• Asia

Currently, North America is the biggest market, accounting for the majority of the total market share.

Competitive Landscape:

The report has also analyzed the competitive landscape of the market, with some of the key players being F. Hoffmann-La Roche Ltd, Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Groupe Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, and Biogen Inc.

Key Questions Answered in This Report:

• How has the global biopharmaceutical industry performed so far and how will it perform in the coming years?
• What are the current and historical manufacturing capacity trends in the biopharmaceutical manufacturing industry?
• What are the key regional markets in the industry?
• What is the breakup of the market based on the class?
• What is the breakup of the market based on the cell culture?
• What is the structure of the industry and who are the key players?

1   Preface
2   Research Methodology and Market Definitions
3   Executive Summary
4   Global Biopharmaceutical Market: Key Trends
    4.1 Biopharmaceuticals are Growing Faster than Small Molecule Drugs
    4.2 Growth of Biosimilars will Push Volumes and Introduce New Players in this Market
    4.3 A Rich Biopharmaceutical Pipeline will Drive the Capacity Demand in the Coming Years
    4.4 Increasing Trends in Mergers and Acquisitions will Increase Redundant Capacities
    4.5 Increasing Focus on Personalized Medicines and High Value Low Volume Markets
    4.6 Higher Titers will Reduce Capacity Demand
    4.7 Growth in the Use of Cost Effective Disposable Technologies
    4.8 Despite Sufficient Global Capacity, Its Uneven Distribution will Continue to Spur Demand
5   Global Biopharmaceutical Market: Industry Performance
    5.1 Current and Historical Sales Trends
    5.2 Market Breakup by Region
    5.3 Market Breakup by Expression Systems
    5.4 Market Breakup by Product Type
    5.5 Market Outlook
     5.6 SWOT Analysis
         5.6.1 Strengths
         5.6.2 Weaknesses
         5.6.3 Opportunities
         5.6.4 Threats
     5.7 Value Chain Analysis
     5.8 Porter’s Five Forces Analysis
         5.8.1 Overview
         5.8.2 Bargaining Power of Buyers
         5.8.3 Bargaining Power of Suppliers
         5.8.4 Degree of Competition
         5.8.5 Threat of New Entrants
         5.8.6 Threat of Substitutes
  6   Regional Biopharmaceutical Market Analysis
      6.1 United States
        6.1.1 Current and Historical Sales Trends
        6.1.2 Market Outlook
     6.2 Canada
        6.2.1 Current and Historical Sales Trends
        6.2.2 Market Outlook
    6.3 United Kingdom
        6.3.1 Current and Historical Sales Trends
        6.3.2 Market Outlook
    6.4 Germany
        6.4.1 Current and Historical Sales Trends
        6.4.2 Market Outlook
    6.5 France
        6.5.1 Current and Historical Sales Trends
        6.5.2 Market Outlook
    6.6 Italy
         6.6.1 Current and Historical Sales Trends
        6.6.2 Market Outlook
    6.7 Spain
        6.7.1 Current and Historical Sales Trends
        6.7.2 Market Outlook
    6.8 Russia
         6.8.1 Current and Historical Sales Trends
         6.8.2 Market Outlook
     6.9 Brazil
         6.9.1 Current and Historical Sales Trends
        6.9.2 Market Outlook
    6.10 Australia
        6.10.1 Current and Historical Sales Trends
        6.10.2 Market Outlook
7   Global Biopharmaceutical Manufacturing Industry
    7.1 Current and Historical Manufacturing Capacity Trends
    7.2 Market Breakup by Region
        7.2.1 North America
            7.2.1.1 Current and Historical Manufacturing Capacity Trends
            7.2.1.2 Market Outlook
        7.2.2 Europe
            7.2.2.1 Current and Historical Manufacturing Capacity Trends
            7.2.2.2 Market Outlook
        7.2.3 Asia
            7.2.3.1 Current and Historical Manufacturing Capacity Trends
            7.2.3.2 Market Outlook
    7.3 Market Breakup by Cell Culture
        7.3.1 Mammalian Cell Culture
            7.3.1.1 Key Market Drivers
            7.3.1.2 Current and Historical Sales Trends
            7.3.1.3 Current and Historical Manufacturing Capacity Trends
            7.3.1.4 Market Breakup by Region
            7.3.1.5 Market Breakup by Product Type
            7.3.1.6 Key Players
            7.3.1.7 Market Outlook
        7.3.2 Microbial Cell Culture
            7.3.2.1 Key Market Drivers
            7.3.2.2 Current and Historical Sales Trends
            7.3.2.3 Current and Historical Manufacturing Capacity Trends
            7.3.2.4 Market Breakup by Product
            7.3.2.5 Market Breakup by Region
            7.3.2.6 Key Players
            7.3.2.7 Market Outlook
    7.4 Market Breakup by Class
        7.4.1 Monoclonal Antibodies
            7.4.1.1 Current and Historical Sales Trends
            7.4.1.2 Market Outlook
        7.4.2 Recombinant Proteins
            7.4.2.1 Current and Historical Sales Trends
            7.4.2.2 Market Outlook
        7.4.3 Interferon
            7.4.3.1 Current and Historical Sales Trends
            7.4.3.2 Market Outlook
        7.4.4 Granulocyte Colony-Stimulating Factor (G-CSF)
            7.4.4.1 Current and Historical Sales Trends
            7.4.4.2 Market Outlook
        7.4.5 Erythropoietin
            7.4.5.1 Current and Historical Sales Trends
            7.4.5.2 Market Outlook
        7.4.6 Recombinant Human Insulin
            7.4.6.1 Current and Historical Sales Trends
            7.4.6.2 Market Outlook
        7.4.7 Vaccines
            7.4.7.1 Current and Historical Sales Trends
            7.4.7.2 Market Outlook
        7.4.8 Human Growth Hormones (HGH)
            7.4.8.1 Current and Historical Sales Trends
            7.4.8.2 Market Outlook
        7.5 Market Outlook
8   Competitive Landscape
    8.1 Market Breakup by Manufacturer Type
        8.1.1 Product Companies
        8.1.2 Contract Manufacturers
    8.2 Key Player Profiles
        8.2.1 Roche
            8.2.1.1 Company Overview
            8.2.1.2 Key Financials
        8.2.2 Amgen
            8.2.2.1 Company Overview
            8.2.2.2 Key Financials
        8.2.3 Novo Nordisk
            8.2.3.1 Company Overview
            8.2.3.2 Key Financials
        8.2.4 AbbVie
            8.2.4.1 Company Overview
            8.2.4.2 Key Financials
        8.2.5 Sanofi S.A
            8.2.5.1 Company Overview
            8.2.5.2 Key Financials
        8.2.6 Johnson & Johnson
            8.2.6.1 Company Overview
            8.2.6.2 Key Financials
        8.2.7 Pfizer
            8.2.7.1 Company Overview
            8.2.7.2 Key Financials
        8.2.8 Merck & Co.
            8.2.8.1 Company Overview
            8.2.8.2 Key Financials
        8.2.9 Lilly
            8.2.9.1 Company Overview
            8.2.9.2 Key Financials
        8.2.10 Biogen Idec
            8.2.10.1 Company Overview
            8.2.10.2 Key Financials          
 

List of Figures

Figure 4-1: Global: Companies Manufacturing or Developing Active Substances for Follow-on Biologics (in no’s)
Figure 4-2: Global: Biopharmaceutical Products: Distribution by Production Technology (in no’s)
Figure 4-3: Global: Biopharmaceuticals: Mergers and Acquisitions Transaction Value (in US$ Billion)
Figure 4-4: Global: Orphan Drug Market: Designated vs Approvals (in no’s), 2005-2016
Figure 4-5: Global: Personalized Medicine Market (in US$ Billion), 2011 and 2018
Figure 4-6: Increase in Titers and Reduction in Capacity Utilization Rate (in %), 2011 and 2018
Figure 4-7: Disposable (Single Use) vs Stainless Steel Bioreactors
Figure 4-8: United States and Western Europe: Capacity Expansion
Figure 5-1: Global: Biopharmaceutical Market: Sales Trend (in US$ Billion), 2011–2018
Figure 5-2: Global: Biopharmaceutical Market: Breakup by Region (in %), 2018
Figure 5-3: Global: Biopharmaceutical Market: Breakup by Various Expression Systems (in %), 2018
Figure 5-4: Global: Biopharmaceutical Market: Expression Systems (Respondents’ Trends), 2011–2018
Figure 5-5: Global: Biopharmaceutical Market: Breakup by Drug Sales (in %), 2018
Figure 5-6: Global: Biopharmaceutical: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 5-7: Global: Biopharmaceutical: SWOT Analysis
Figure 5-8: Global: Biopharmaceutical: Value Chain Analysis
Figure 5-9: Global: Biopharmaceutical: Porter’s Five Forces Analysis
Figure 6-1: United States: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-2: United States: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-3: Canada: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-4: Canada: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-5: United Kingdom: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-6: United Kingdom: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-7: Germany: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-8: Germany: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-9: France: Biopharmaceutical Market: Sales Trend (in Million US$), 2011–2018
Figure 6-10: France: Biopharmaceutical Market: Sales Trend Forecast (in Million US$), 2019–2024
Figure 6-11: Italy: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-12: Italy: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-13: Spain: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-14: Spain: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-15: Russia: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-16: Russia: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-17: Brazil: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-18: Brazil: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 6-19: Australia: Biopharmaceutical Market: Sales Trend (in US$ Million), 2011–2018
Figure 6-20: Australia: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2019–2024
Figure 7-1: Global: Biopharmaceutical Manufacturing: Capacity Trends (in Kilo Liters), 2011–2018
Figure 7-2: Global: Biopharmaceuticals Manufacturing: Capacity Breakup by Region (in %), 2018
Figure 7-3: North America: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2011–2018
Figure 7-4: North America: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 7-5: Europe: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2011–2018
Figure 7-6: Europe: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 7-7: Asia: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2011–2018
Figure 7-8: Asia: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 7-9: Global: Mammalian Products: Sales Trend (in US$ Billion), 2011–2018
Figure 7-10: Global: Mammalian Cell Culture: Capacity Trend (in Kilo Liters), 2011–2018
Figure 7-11: Global: Mammalian Cell Culture: Capacity Utilization Trend (in %), 2011–2018
Figure 7-12: Global: Mammalian Cell Culture: Capacity Trends by Region (in Kilo Liters), 2011–2018
Figure 7-13: Global: Mammalian Cell Culture: Demand Breakup of Commercial Antibody Products (in %), 2018
Figure 7-14: Global: Mammalian Cell Culture: Market Breakup by Key Players (in %), 2018
Figure 7-15: Global: Mammalian Products: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-16: Global: Mammalian Cell Culture: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 7-17: Global: Mammalian Cell Culture: Capacity Trends Forecast by Region (in Kilo Liters), 2019–2024
Figure 7-18: Global: Microbial Products: Sales Trend (in US$ Billion), 2011–2018
Figure 7-19: Global: Microbial Cell Culture: Capacity Trend (in Kilo Liters), 2011–2018
Figure 7-20: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trend (in Kilo Liters), 2011–2018
Figure 7-21: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trend (in Kilo Liters), 2011–2018
Figure 7-22: Global: Microbial Cell Culture: Capacity Utilization Trend (in %), 2011–2018
Figure 7-23: Global: Microbial Cell Culture: Demand Breakup of Commercial Products (in %), 2018
Figure 7-24: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trends by Region (in Kilo Liters), 2011–2018
Figure 7-25: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trends by Region (in Kilo Liters), 2011–2018
Figure 7-26: Global: Microbial Cell Culture: Market Breakup by Key Players (in %), 2018
Figure 7-27: Global: Microbial Products: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-28: Global: Microbial Products: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 7-29: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trends Forecast by Region (in Kilo Liters), 2019–2024
Figure 7-30: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trends Forecast by Region (in Kilo Liters), 2019–2024
Figure 7-31: Global: Monoclonal Antibodies: Sales Trend (in US$ Billion), 2011–2018
Figure 7-32: Global: Monoclonal Antibodies: Sales Trend (in US$ Billion), 2019–2024
Figure 7-33: Global: Recombinant Proteins: Sales Trend (in US$ Billion), 2011–2018
Figure 7-34: Global: Recombinant Proteins: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-35: Global: Interferon: Sales Trend (in US$ Billion), 2011–2018
Figure 7-36: Global: Interferon: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-37: Global: Granulocyte Colony-Stimulating Factor (G-CSF): Sales Trend (in US$ Billion), 2011–2018
Figure 7-38: Global: Granulocyte Colony-Stimulating Factor (G-CSF): Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-39: Global: Erythropoietin: Sales Trend (in US$ Billion), 2011–2018
Figure 7-40: Global: Erythropoietin: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-41: Global: Recombinant Human Insulin: Sales Trend (in US$ Billion), 2011–2018
Figure 7-42: Global: Recombinant Human Insulin: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-43: Global: Vaccines: Sales Trend (in US$ Billion), 2011–2018
Figure 7-44: Global: Vaccines: Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-45: Global: Human Growth Hormones (HGH): Sales Trend (in US$ Billion), 2011–2018
Figure 7-46: Global: Human Growth Hormones (HGH): Sales Trend Forecast (in US$ Billion), 2019–2024
Figure 7-47: Global: Biopharmaceutical Manufacturing: Capacity Trend Forecast (In Kilo Liters), 2019–2024
Figure 8-1: Global: Biopharmaceutical Manufacturing: Capacity Breakup by Manufacturer Type (in %), 2018
Figure 8-2: Global: Biopharmaceutical Manufacturing: Capacity Breakup Forecast by Manufacturer Type (in %), 2024
Figure 8-3: Global: Biopharmaceutical Product Companies: Capacity Trend (in Kilo Liters), 2011–2018
Figure 8-4: Global: Biopharmaceutical Product Companies: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 8-5: Global: Biopharmaceutical CMOs: Capacity Trend (in Kilo Liters), 2011–2018
Figure 8-6: Global: Biopharmaceutical CMOs: Capacity Trend Forecast (in Kilo Liters), 2019–2024
Figure 8-7: Roche: Sales Value Trend (in Billion US$), 2012-2017
Figure 8-8: Roche: Revenue Breakup by Region (in %), 2017
Figure 8-9: Amgen: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-10: Amgen: Revenue Breakup by Region (in %), 2017
Figure 8-11: Novo Nordisk: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-12: Novo Nordisk: Revenue Breakup by Region (in %), 2017
Figure 8-13: AbbVie: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-14: AbbVie: Revenue Breakup by Region (in %), 2017
Figure 8-15: Sanofi S.A: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-16: Sanofi S.A: Revenue Breakup by Region (in %), 2017
Figure 8-17: Johnson & Johnson: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-18: Johnson & Johnson: Revenue Breakup by Region (in %), 2017
Figure 8-19: Pfizer: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-20: Pfizer: Revenue Breakup by Region (in %), 2017
Figure 8-21: Merck & Co: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-22: Merck & Co: Revenue Breakup by Region (in %), 2017
Figure 8-23: Lilly: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-24: Lilly: Revenue Breakup by Region (in %), 2017
Figure 8-25: Biogen Idec: Sales Value Trend (in Billion USD), 2012-2017
Figure 8-26: Biogen Idec: Revenue Breakup by Region (in %), 2017

List of Tables

Table 4-1: Global: Small Molecule Sales vs. Biopharmaceutical Sales (in Billion US$), 2011–2018
Table 8-1: Roche: Financial Data (2012-2017)
Table 8-2: Amgen: Financial Data (2012-2017)
Table 8-3: Novo Nordisk: Financial Data (2012-2017)
Table 8-4: AbbVie: Financial Data (2012-2017)
Table 8-5: Sanofi S.A: Financial Data (2012-2017)
Table 8-6: Johnson & Johnson: Financial Data (2012-2017)
Table 8-7: Pfizer: Financial Data (2012-2017)
Table 8-8: Merck & Co: Financial Data (2012-2017)
Table 8-9: Lilly: Financial Data (2012-2017)
Table 8-10: Biogen Idec: Financial Data (2012-2017)